Acción RECIPHARM PUBL AB
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate
Instrumento Inactivo

Otros idiomas Recipharm publ AB Swiss Exchange

Acciones

SE0005757267

Precio de cierre Swiss Exchange
Otros sitios de cotización
- SEK - Gráfico intradía de Recipharm publ AB
2023 Synokem Pharmaceuticals Limited adquirió a Recipharm AB (publ) una participación del 74% en Nitin Lifesciences Limited. CI
2023 Recipharm anuncia cambios en su CEO CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Åsa Bergström New COO at Nanologica AB (publ)
Blue Wolf Capital to Acquire OSD CDMO Sites from Recipharm
Blue Wolf Capital Partners LLC agreed to acquire Seven manufacturing and development facilities of Recipharm AB.
Recipharm attains major sustainability milestones
Recipharm, Medspray, and Resyca enter into exclusive license agreement to develop nasally-delivered drug products using proprietary soft mist technology
ReciBioPharm partners with Acuitas Therapeutics to provide rapid technology transfers and CGMP manufacture of Acuitas LNP formulations
Recipharm announces collaboration with Oz-UK to accelerate the development of low global warming potential pMDIs utilising HFA-152a propellant
Synokem Pharmaceuticals Limited acquired 74% stake in Nitin Lifesciences Limited from Recipharm AB.
Recipharm Announces CEO Changes
Recipharm Appoints Marc Funk as Board of Directors
Marc Funk to transition to Recipharm's Board of Directors, Greg Behar appointed new CEO, Inhaled Business to standalone in 2024
Fitch Affirm Recipharm at 'B'; Outlook Stable.
Recipharm - Earthquake in Morocco
Recipharm partners with Ahead Therapeutics to develop rare autoimmune disease therapy
Recipharm Announces Executive Appointments
Recipharm and Honeywell to speed development of inhalers with a near-zero global warming potential propellant
Recipharm's new analytical lab brings impressive testing capabilities to global markets
NewBiologix SA announced that it has received CHF 45 million in funding from Recipharm AB and other investors
Recipharm Appoints Vikas Gupta as President of ReciBioPharm
Arranta Bio, a Recipharm company, signs contract with MIT to develop rapid manufacturing of mRNA therapeutics
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción RECI B
  4. Acción
  5. Noticias Recipharm publ AB
  6. Otros idiomas